Dr. Lauren Kim speaks with Adarsh Mallepally and Dr. Cory Trankle about their large-scale retrospective study of nearly 4 million patients examining the risk of nephrogenic systemic fibrosis after gadolinium-based contrast administration in those with advanced renal dysfunction. They discuss how modern group 2 and macrocyclic agents were associated with an exceedingly low incidence of NSF, offering important reassurance for evidence-based contrast use and evolving clinical practice.

Nephrogenic Systemic Fibrosis in Patients with Advanced RenalDysfunction Following Gadolinium-based Contrast Agents. Mallepally et al. Radiology 2025; 317(3):e251794.